Concerns about the delta variant, the potential need for annual booster shots and the possibility of expanding the vaccines to children have investors hopeful that Covaxin will still eventually be a huge payoff for Ocugen. Realistically, Ocugen is probably looking at potential approval of Covaxin in mid-2023 at the earliest. 1125 N. Charles St, Baltimore, MD 21201. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. 1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell, 3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street, 2 Reasons to Avoid a Roth 401(k) for Your Retirement Savings, Warren Buffett's Latest $2.9 Billion Buy Brings His Total Investment in This Stock to $66 Billion in 4 Years, Want $1 Million in Retirement? These symbols will be available throughout the site during your session. Theres even room for more lines. Ocugens Big Run: One company that has been a home-run investment in the last year has been biotech stock Ocugen Inc (NASDAQ:OCGN). CanSinoBio will be able to fund much of the development of OCU300, Ocugens flagship product that targets oGVHD (ocular graft versus host disease), a common complication of bone marrow transplants. And while Ocugen will need more capital at some point, the company at least has time to push OCU300 forward and get its story out to investors. The equity has experienced a continual decline for years. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. However, due to the fact the details of the definitive agreement have yet to be finalized, in addition to the current lack of insight into the U.S. regulatory pathway or commercial strategy, Ramakanth stays on the sidelines for now. OCGN does not even appear to have an apparent reason to exist. Its certainly possible the deal will fall through, leaving Ocugen with just the $15.8 million in cash with which it closed the third quarter, according to its 10-Q. Investors who have owned stocks in the last year have generally experienced some big gains. Article printed from InvestorPlace Media, https://investorplace.com/2020/01/ocugen-stock-faint-heart/. That product drives the current bull case for Ocugen stock. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. The Ocugen 52-week low stock price is 0.93, which is 1.1% below the current share price. It announced on Dec. 9 of last year 17 months later that it was 50% through enrollment. Literally, zero. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The Motley Fool has a disclosure policy. Biotech companies have emerged from similar levels to become huge winners, as evidenced simply by looking at some of the best biotech stocks for 2019. The company has a gene therapy platform as well as two preclinical compounds that aim to treat retinal diseases. That's right -- they think these 10 stocks are even better buys. It took Moderna roughly 10 months from the initiation of the late-stage study for its COVID-19 vaccine to the point where the company filed for full FDA approval. Investors were hopeful that the small drugmaker would be able to win U.S. The generic form of brimonidine, the active ingredient, is not approved for the condition, according to Ocugens most recent presentation. In November, Bharat Biotech began Phase 3 testing of Covaxin in India. Bharat's offering COVAXIN, a whole-viron inactivated COVID-19 vaccine candidate, has already shown promise in Phase 1 and 2 clinical trials in India and the enrollment of 26,000 subjects for the Phase 3 study is currently underway. Start trading Options with Saxo today. Healthy companies do not undergo 1-for-60 reverse stock splits like this one did in September 2019. Ocugen abandoned its pursuit of a U.S. EUA for Covaxin in immunizing adults last year. Indeed, the price broke below the 24 December 2018 low at 4.81 and is currently attempting a return move. It has real products. CanSinoBio will receive some of the profits, but Ocugen still would skyrocket with FDA approval and ensuing revenue and there are more products in the pipeline. While it feels cool to buy a thousand shares of OCGN stock vs. a few shares of Amazon (NASDAQ:AMZN), save yourself the heartache. Most biotech companies have intriguing stories on paper; Ocugen is no different. For example, after the FDA revised its guidelines for the EUA process for COVID-19 vaccines, Ocugen's CEO stated, "Since we have been in discussions with the FDA since late last year, we do not believe that the FDA's recently revised guidance regarding EUAs raises any concerns about our ability to submit the EUA for Covaxin as planned." When the market crashed during the U.S. pandemic outbreak in March, shares of vaccine makers understandably soared as work began on developing vaccines to fight COVID-19. Maybe. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. However, the Strong Buy consensus rating is backed with a $0.9 price target, which implies downside of 68% from current levels. In fact, the SPDR S&P 500 (NYSE:SPY) total return over the last 12 months is 34.2%. That's not going to happen now. The FDA's decision not to issue EUA really wasn't all that surprising, though. *Stock Advisor returns as of November 20, 2020. These options will be cheaper than owning the stock itself. The content is intended to be used for informational purposes only. For most of its history, what we now know as Ocugen stock was Histogenics, a cell therapy company focused on orthopedics. Matt McCall and the InvestorPlace Research Staff, statistics support having long-term exposure, Click here to see what Matt has up his sleeve now, There Are So Many Stocks to Buy Ocugen Isnt One of Them. The first is that Ocugen is facing potential delisting from the NASDAQ given that its share price still sits well below $1. But theres a big difference in having an edge flipping sub-$5 stocks vs. combing over this group as an investor looking for sound fundamentals and a mistakenly low stock price. 2023 InvestorPlace Media, LLC. Long-term debt of $1.6 million is not a back-breaker either. It means that institutional investors focused on the sector largely have passed on the pipeline. If Ocugen goes up, you can still profit. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Ocugen, previously a private company, instituted a reverse merger, which they completed on Sep. 30. A partnership with a respected Asian biotechnology company offers some validation to the pipeline, and a key product is progressing through Phase III trials. What Is the Best EV Stock to Buy Now? Ocugen stated in a press release that it plans to "continue working with the FDA to evaluate the regulatory pathway for the pediatric use of Covaxin." From a near-term standpoint, there are two key risks. It peaked at a split-adjusted level of around $778 per share soon after its initial public offering in 2014. Its top officers have experience at Pfizer (NYSE:PFE) and other well-respected pharmaceutical and biotechnology companies. That's right -- they think these 10 stocks are even better buys. Please check your download folder. Investors should worry about companies with no revenue even under the best of circumstances. Names like Ocugen (NASDAQ:OCGN) arent trading for about 50 cents apiece by accident. The FDA typically takes 60 days to accept a regulatory filing then 10 months to make an approval decision. The Nasdaq has been even more impressive, rallying 67.7% in the same time frame and hitting new all-time highs in the process. With no effective treatments, and without a clear reason to exist, I would avoid buying Ocugen stock even as a speculative play. Malvern-based biopharmaceutical company Ocugen completed its previously announced $100 million private stock sale. Keith Speights has no position in any of the stocks mentioned. Under the terms of the agreement, Ocugen is entitled to 45% of the profits from the commercialization of Covaxin in the U.S. and Canada. This requires no immediate effort on your part. MALVERN, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Unfortunately, both the merger and the reverse split have failed to stem the decline of former Histogenics stock. Lorem ipsum dolor sit amet, consectetur adipiscing elit. The sale of NeoCart, which still is pending, can bring in another $8 million, based on the current agreement. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! Biotechnology stocks like Ocugen (NASDAQ:OCGN) are among the markets riskiest plays. Ocugen had to go an unusual route to go public. Thats why we give you a wide range of Options on stocks, indices, commodities and FX. In fact, $1,000 in Ocugen stock bought on Aug. 9, 2020, would be worth about $15,100 today. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. Now, with the stock trading near the 40-cent per share level, its prospects have taken a dramatic turn for the worse. Keith Speights has no position in any of the stocks mentioned. Add in a $31 million market capitalization and potentially significant cash burn, and Ocugen stock self-evidently is not for risk-averse investors. Why Ocugen Stock Is Crashing Today By Keith Speights - Mar 4, 2022 at 11:42AM Key Points The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. Theres an opportunity here. Ocugen Inc First Quarter 2022 Financial Results and Recent Business Highlights 04/21/2022 Noble Capital Markets' Eighteenth Annual Investor Conference 03/14/2022 34th Annual ROTH Conference 02/25/2022 Ocugen, Inc. Q4 and Full Year 2021 Financial Results and Recent Business Highlights 01/10/2022 H.C. Wainwright Bioconnect Conference 12/22/2021 Investors need to understand the risk profile here. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. This decision. Ocugen Inc. stock rises Wednesday, outperforms market Feb. 22, 2023 at 5:14 p.m. The biotech stock promptly crashed by more than 30%. You can be a growth investor, futures trader, deep-value investor, a day trader, options player, or a dividend aficionado. OCU300 already has received an orphan drug designation from the U.S. Food & Drug Administration for oGVHD; there is no currently approved treatment in the U.S. Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. Related Link: If You Invested $1,000 In Moderna Stock One Year Ago, Here's How Much You'd Have Now. Remember, though, that Moderna achieved this while working closely with the U.S. government (including receiving funding from Uncle Sam) and during a period when vaccines weren't widely available. Ill be sticking to the stocks that are actually working. The Motley Fool has a disclosure policy. In December, Ocugen stated that it had put together an advisory board of "leading academic and industry experts to evaluate the clinical and regulatory path to approval in the U.S. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. Still, Ocugens balance sheet isnt as dire as its share price might suggest. Conditions only seem to get worse for Ocugen (NASDAQ:OCGN). Why Everyone Is Investing in 5G All WRONG, Americas #1 Stock Picker Reveals His Next 1,000% Winner, Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company, Radical New Battery Could Dismantle Oil Markets. Copyright market." The average price target among the five analysts covering the stock is $6, suggesting 27.9% downside from current levels. The Ocugen deal is a way to salvage some limited value. CEO Shankar Musunuri stated that he was "pleased to say" that Ocugen was in discussions with the FDA about the data it had submitted for the pediatric EUA. But there is no question some big-name stocks performed better than others along the way. The second is that the balance sheet still needs some help. Copy and paste multiple symbols separated by spaces. The reverse merger that brought Ocugen to the public markets led to huge losses but some investors are buying the dip. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. *Stock Advisor returns as of June 7, 2021. More importantly, the 5-star analyst added, COVAXIN also induces comparable levels of neutralizing antibodies to those in human convalescent serum," which, the analyst believes," bodes well for the success of the ongoing Phase 3 trial in India.. You could sell some or all of your Ocugen shares and buy long-term call options on the stock. Nano-cap biotech play Ocugen has an intriguing story and a ton of risk. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. 7 Penny Stocks Poised for Explosive Growth in 2023, Ocugen Stock Is Not for the Faint of Heart. quotes delayed at least 15 minutes, all others at least 20 minutes. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. Investors appear to expect that Bharat's big win for Covaxin in India could translate to success for Ocugen in the U.S. On Dec. 22, Ocugen and Bharat announced a binding letter of intent to jointly develop Covaxin for the U.S. market. Create your Watchlist to save your favorite quotes on Nasdaq.com. I am all for a good opportunity, but I dont know why some investors insist on penny stocks. From the outside looking inward, it looks like a marriage of two people who got together simply because nobody else would take them. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Considering Bharats reputation for world-class R&D and manufacturing capabilities in vaccines and bio-therapeutics, H.C. Wainwright analyst Swayampakula Ramakanth thinks the company is a suitable partner.. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! Even before that point, the most promising candidates generally can find funding. MALVERN, Pa., May 29, 2018 /PRNewswire/ -- Ocugen, Inc., a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular diseases, today announced that it will present at the 2018 BIO International Convention, taking place June 4-7, 2018, in Boston. Some of the names will rally big, putting together epic squeezes that can double or triple the stock prices in just a few days. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. Ocugen came to the market via what was essentially a reverse merger with Histogenics Corporation, a deal that closed at the end of September. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. As of this writing, Vince Martin has no positions in any securities mentioned. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization (EUA) in India for COVID-19 vaccine Covaxin. Instead of buying a piece of the S&P 500 or Nasdaq or even better, a common sense mega-holding like Apple (NASDAQ:AAPL) or Amazon investors in OCGN stock took on a high-risk investment and for months saw negative returns. The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. The short answer is: everything. Another alternative is to sell some or all of your Ocugen stock and invest the money elsewhere. So, what goes wrong? Moreover, Histogenics existed to treat orthopedic conditions, while Ocugen focused on rare eye diseases. Ocugen Inc., formerly known as Histogenics Cp, is based in Malvern, Pennsylvania. The next key catalyst for the biotech stock could be the announcement of the details of the plan to win EUA for Covaxin in the U.S. market. Custom BMW. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization. For investors new to the story, there are some positives when it comes to OCGN stock. But any success they find will be without me as a shareholder. ET by MarketWatch Automation Ocugen Inc. stock falls Tuesday, underperforms market Feb. 21, 2023 at 5:14. Ocugen has responded to Health Canada regarding deficiencies identified with its regulatory filing for Covaxin. Historical daily share price chart and data for Ocugen since 2023 adjusted for splits. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. Copyright 2023 InvestorPlace Media, LLC. Considering the conditions facing the company, I do not recommend Ocugen stock regardless of risk tolerances. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Type a symbol or company name. Histogenics itself highlights the risks involved in small-cap biotech. The vaccine reportedly has a 78% efficacy rate against COVID-19, significantly lower than leading vaccines granted FDA emergency authorization. *Average returns of all recommendations since inception. The Motley Fool->. Sign up below to get this incredible offer! The OCGN stock forecast 2022 outlook suggests that Ocugen's stock may struggle in the short term. However, the marriage of Histogenics and Ocugen looks destined to end in a suicide pact instead of a mere divorce. Making the world smarter, happier, and richer. The Ocugen deal is a way to salvage some limited value. Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. COVID-19 vaccines from Pfizer and Moderna are already on the market in the U.S. with efficacy levels of 94% or greater. Matthew McCall left Wall Street toactually helpinvestors by getting them into the worlds biggest, most revolutionary trends BEFORE anyone else. Shares of Ocugen (OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based Bharat Biotech to co-develop a COVID-19 vaccine for the U.S. market. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page.